{"id":"NCT00820222","sponsor":"Novartis Pharmaceuticals","briefTitle":"Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer","officialTitle":"A Randomized, Multicentre, Open-Label, Phase III Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Anthracycline- or Taxane-Exposed ErbB2-Positive Metastatic Breast Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-04-14","primaryCompletion":"2012-06-11","completion":"2018-03-22","firstPosted":"2009-01-12","resultsPosted":"2013-03-15","lastUpdate":"2019-04-02"},"enrollment":540,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Metastases, Brain"],"interventions":[{"type":"DRUG","name":"capecitabine","otherNames":[]},{"type":"DRUG","name":"lapatinib","otherNames":[]},{"type":"DRUG","name":"trastuzumab","otherNames":[]}],"arms":[{"label":"Lapatinib plus capecitabine","type":"EXPERIMENTAL"},{"label":"Trastuzumab plus capecitabine","type":"ACTIVE_COMPARATOR"}],"summary":"This open label study was designed to evaluate Lapatinib effect on incidence of brain metastases in ErbB2 (HER2) positive metastatic breast cancer patients exposed to prior taxanes or anthracyclines.","primaryOutcome":{"measure":"Number of Participants With Central Nervous System (CNS) Metastases (as Assessed by Independent Review) as the Site of First Relapse","timeFrame":"From randomization until disease progression, death, or discontinuation from the study (average of 10 months). Cut-off 11-Jun-2012","effectByArm":[{"arm":"Lapatinib Plus Capecitabine","deltaMin":8,"sd":null},{"arm":"Trastuzumab Plus Capecitabine","deltaMin":12,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.360"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":17},"locations":{"siteCount":164,"countries":["United States","Belgium","Denmark","France","Germany","Greece","Hungary","Italy","Poland","Russia","Spain","Sweden","Thailand","United Kingdom"]},"refs":{"pmids":["25605838"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":41,"n":270},"commonTop":["Palmar-plantar erythrodysaesthesia syndrome","Diarrhoea","Nausea","Asthenia","Rash"]}}